Multi-Component Intervention for Vaccine Hesitancy

Phase-Based Progress Estimates
Vaccine Hesitancy+3 More
Community Event - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial will study how well educational materials about vaccines work in increasing the number of parents who vaccinate their middle school-aged children.

Eligible Conditions
  • Vaccine Hesitancy
  • Communicable Diseases in Children

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 1 year

Year 1
Intention by parents to vaccinate school-aged children, as measured by survey
Up to 1 year
Rates of recommended vaccination among school-aged children

Trial Safety

Trial Design

2 Treatment Groups

Usual Care
1 of 2
Multi-Component Intervention
1 of 2

Active Control

148 Total Participants · 2 Treatment Groups

Primary Treatment: Multi-Component Intervention · No Placebo Group · N/A

Usual CareNoIntervention Group · 1 Intervention: Usual Care · Intervention Types:
Multi-Component InterventionActiveComparator Group · 2 Interventions: Community Event, Educational Material · Intervention Types: Behavioral, Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,658 Previous Clinical Trials
4,955,137 Total Patients Enrolled
Milton S. Hershey Medical CenterLead Sponsor
456 Previous Clinical Trials
2,784,190 Total Patients Enrolled
Jennifer KraschnewskiPrincipal InvestigatorPenn State College of Medicine
1 Previous Clinical Trials
136 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: November 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.